Biomed Industries, Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on February 3, 2025 - 22:21 GMT

Biomed Industries, Inc. Engages with Medicare to Advance Oral Bioglutide as an Affordable Metabolic Disorder Treatment

Biomed Industries, Inc. Engages with Medicare to Advance Oral Bioglutide (NA-931) as an Affordable Treatment for obesity and other metabolic disorders SAN JOSE, CA, UNITED STATES, February 3, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) …

Distribution channels: Chemical Industry, Companies ...

Published on January 16, 2025 - 11:00 GMT

Biomed Industries, Inc. Expands Patent Protection for Novel Combination Therapy Targeting Obesity

Biomed Industries, Inc. Expands Patent Protection for Novel Combination Therapy Targeting Obesity SAN JOSE, CA, UNITED STATES, January 16, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) announced today at the JP Morgan Healthcare Conference …

Distribution channels: Chemical Industry, Companies ...

Published on December 18, 2024 - 17:09 GMT

Biomed Industries, Inc. to Present Promising Data on NA-931, a Quadruple Receptor Agonist for Obesity and Hypertension

Biomed Industries, Inc. to Present Promising Data on NA-931, a Quadruple Receptor Agonist for Obesity and Hypertension at the ICHH 2025 in Tokyo SAN JOSE, CA, UNITED STATES, December 18, 2024 /⁨EINPresswire.com⁩/ -- San Jose, CA — December 18, 2024 — …

Distribution channels: Chemical Industry, Companies ...

Published on December 10, 2024 - 11:00 GMT

Biomed Industries, Inc. to Present Combination Therapy Phase 2 Protocol of NA-931 and Tirzepatide at ICOCD-2025

Biomed Industries, Inc. will present combination therapy phase 2 clinical protocol of NA-931 and Tirzepatide at ICOCD on January 2–3, 2025, in Seattle, WA SAN JOSE, CA, UNITED STATES, December 10, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...

Published on November 25, 2024 - 21:13 GMT

Biomed Industries, Inc. Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder

Biomed Industries, Inc. Unveils Groundbreaking Research on NA-931 as a Potential Treatment for Alcohol Use Disorder at World Conference on Addiction Medicine SAN JOSE, CA, UNITED STATES, November 25, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...

Published on November 4, 2024 - 11:00 GMT

Biomed Industries Presented Phase I Results of its Oral Quadruple Receptor Agonist NA-931 at World Obesity Congress 2024

Biomed Industries, Inc. presented Phase 1 results of NA-931, an Oral Novel Quadruple Receptor Agonist for Weight Loss at the World Obesity Congress 2024 SAN JOSE, CA, UNITED STATES, November 4, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a …

Distribution channels: Chemical Industry, Companies ...

Published on October 21, 2024 - 10:00 GMT

Biomed Industries Presents Phase I Results of its Oral Quadruple Receptor Agonist NA-931 at the 2024 Obesity Conference

Biomed Industries, Inc. Presents Positive Phase I Results for Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment at Obesity International Conference SAN JOSE, CA, UNITED STATES, October 21, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. …

Distribution channels: Chemical Industry, Companies ...

Published on October 7, 2024 - 10:00 GMT

Biomed Industries, Inc. Reports Positive Phase I Results of Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment

Biomed Industries, Inc. Announces Positive Phase I Results for NA-931, an Oral Quadruple Receptor Agonist for the Treatment of Obesity SAN JOSE, CA, UNITED STATES, October 7, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. announced positive` results …

Distribution channels: Chemical Industry, Companies ...

Published on September 23, 2024 - 09:00 GMT

Biomed Industries Unveils Novel Quadruple Receptor Agonist for Weight Loss at International Obesity Conference

Biomed Industries Unveils Novel Quadruple Receptor Agonist for Weight Loss with Minimal Adverse Effects at the International Obesity Conference in Las Vegas SAN JOSE, CA, UNITED STATES, September 23, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a …

Distribution channels: Chemical Industry, Companies ...

Published on September 9, 2024 - 07:03 GMT

Biomed Industries Unveils a New Neurogenesis Hypothesis with Clinical Data for Alzheimer's and Depression Treatment

Biomed Industries, Inc. Unveils a New Neurogenesis Hypothesis with Clinical Data of NA-831 for Alzheimer's and NA-901 for Major Depressive Disorder Treatment SAN JOSE, CA, UNITED STATES, September 9, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries …

Distribution channels: Chemical Industry, Companies ...

Published on August 26, 2024 - 09:00 GMT

Alzheimer's Disease and Obesity: Biomed Industries, Inc. Unveils Groundbreaking Link and New Treatment Approach

Biomed Industries revealed groundbreaking research on the close relationship between Alzheimer’s Disease and Diabetes-Obesity through its drug developments. SAN JOSE, CA, USA, August 26, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed), a …

Distribution channels: Chemical Industry, Companies ...

Published on August 19, 2024 - 09:00 GMT

Biomed Industries, Inc. Presents Groundbreaking Research on the Link Between Alzheimer’s Disease and Stroke

Biomed Industries, Inc. presents research on the link between Alzheimer’s Disease (AD) and Stroke with clinical studies of NA-831 for AD and NA-911 for Stroke SAN JOSE, CALIFORNIA, USA, August 19, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...

Published on August 5, 2024 - 10:00 GMT

Biomed Industries, Inc. Presents the First Phase 3 Combination Therapy Clinical Trial Protocol for Alzheimer’s Disease

Biomed Industries, Inc. Presents the First Phase 3 Clinical Protocol of Combination Therapy of NA-831 and Lecanemab for the Treatment of Alzheimer's Disease SAN JOSE, CALIFORNIA, UNITED STATES, August 5, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries …

Distribution channels: Chemical Industry, Companies ...

Published on July 9, 2024 - 10:00 GMT

Biomed Industries, Inc. to Present Five Pivotal Papers on Alzheimer’s Disease Therapy at AAIC 2024-Philadelphia

Biomed Industries, Inc. to Present Five Pivotal Papers including latest advancements in combination therapy for Alzheimer’s Disease at AAIC 2024 -Philadelphia SAN JOSE, CALIFORNIA, UNITED STATES, July 9, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, …

Distribution channels: Chemical Industry, Companies ...

Published on July 1, 2024 - 10:00 GMT

Biomed Presents NA-931 and NA-941 for Treatment of Obesity and MASH at ADA Conference and Global MASLD Congress 2024

Biomed Industries, Inc. presents NA-931 and NA-941 for Treatment of Obesity and MASH at ADA's 84th Scientific Sessions and 7th Global MASLD Congress 2024 SAN JOSE, CA, USA, July 1, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed), a …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on June 11, 2024 - 12:00 GMT

Biomed Industries, Inc. to Present a New Quadruple Agonist for Weight Loss at ADA Congress and Euro Obesity Conference

Biomed Industries, Inc. to Present a New Quadruple Receptor Agonist for Treatment of Obesity at ADA’s 84th Scientific Sessions and Euro Obesity Conference-2024 SAN JOSE, CA, USA, June 11, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed), a …

Distribution channels: Chemical Industry, Companies ...

Published on May 6, 2024 - 10:00 GMT

Biomed Industries, Inc. Announces Breakthrough Drug for the Treatment and Prevention of Stroke

Biomed's NA-911 represents a breakthrough in stroke treatment, focusing on neurogenesis showing potential in the treatment of stroke and facilitating recovery. SAN JOSE, CALIFORNIA, UNITED STATES, May 6, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries …

Distribution channels: Chemical Industry, Companies ...

Published on March 12, 2024 - 12:49 GMT

Biomed Industries, Inc. announces the first Triple IGF-1/GLP-1/GIP receptor agonist NA-931 for the treatment of obesity

NA-931, an oral drug and the triple receptor agonist, reduces body weight up to 26% without muscle loss and less adverse events than existing treatments. SAN JOSE, CALIFORNIA, UNITED STATES, March 12, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. …

Distribution channels: Business & Economy, Chemical Industry ...

Published on October 4, 2023 - 12:00 GMT

Biomed Industries, Inc. to showcase its research at Clinical Trials on Alzheimer’s Disease Conference 2023 in Boston

Biomed highlights failure of anti-amyloid drugs, presenting new neurogenesis hypothesis and clinical results of NA-831 for treatment of Alzheimer's disease SAN JOSE, CA, USA, October 4, 2023 /⁨EINPresswire.com⁩/ -- Biomed Industries,™ Inc. Showcases …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...